SinoMab Announces Clinical Results on its First-in-target SM03 at EULAR 2020 Congress
- Written by ACN Newswire
HONG KONG, Jun 10, 2020 - (ACN Newswire) - SinoMab BioScience Limited ("SinoMab" or the "Company", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, made an oral presentation titled "Efficacy and...
Read more: SinoMab Announces Clinical Results on its First-in-target SM03 at EULAR 2020 Congress